A Children's Hospital of Philadelphia team said their case study highlighted the need for increased safety monitoring.
GSK added ROS1 inhibitor to its pipeline through its $10.6 billion acquisition of Nuvalent earlier this month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results